UroGen Pharma Ltd. Retrospective Study Reveals Lower Stricture Rate And Comparable Oncological Outcomes With Antegrade Administration Of JELMYTO Versus Retrograde Administration
Portfolio Pulse from Happy Mohamed
UroGen Pharma Ltd. (NASDAQ:URGN) highlights results of a sub-analysis comparing antegrade and retrograde administration of JELMYTO for low-grade upper tract urothelial cancer treatment. The study found lower stricture rates and comparable oncological outcomes with antegrade administration.
June 20, 2023 | 12:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's study results show potential advantages of antegrade administration of JELMYTO, which may increase confidence in the treatment and boost demand.
The study results show that antegrade administration of JELMYTO has lower stricture rates and comparable oncological outcomes compared to retrograde administration. This may increase confidence in the treatment among physicians and patients, leading to higher demand for JELMYTO and potentially positively impacting UroGen Pharma's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100